Additional Hetero Ring Patents (Class 514/397)
  • Patent number: 10376495
    Abstract: Described herein are compound for the modulation of the G-CSF receptor. The compounds may act as agonists, antagonists, and/or mixed or partial agonists/antagonists of G-CSF. Further provided herein are methods of treating a condition, including, for example, a neurodegenerative disease, by administering a compound as detailed herein.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 13, 2019
    Assignees: University of South Florida, The United States Government as Represented by the Department of Veterans, H. Lee Moffitt Cancer Center and research Institute Inc.
    Inventors: Juan Sanchez-Ramos, Vasyl Sava, Shijie Song, Said Sebti
  • Patent number: 10307401
    Abstract: The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of these compositions in the treatment of prostate cancer.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: June 4, 2019
    Assignee: California Institute of Technology
    Inventors: Peter B. Dervan, Nickolas G. Nickols, Fei Yang, Alexis A. Kurmis
  • Patent number: 10246413
    Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 2, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • Patent number: 10112943
    Abstract: The present invention is concerned with novel tricyclic 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, L, Y, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 30, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: François Paul Bischoff, Henricus Jacobus Maria Gijsen, Frans Alfons Maria Van den Keybus, Frederik Jan Rita Rombouts
  • Patent number: 10076511
    Abstract: The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (IPF), emphysema of the lungs, chronic obstructive pulmonary disease (COPD) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on Treamide. The latter is a bisamide derivative of dicarboxylic acid of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Treamid Therapeutics GmbH
    Inventors: Vladimir Evgenievich Nebolsin, Anastasia Vladimirovna Rydlovskaya, Alexandr Mikhailovich Dygai, Tatiana Gennadievna Borovskaya, Evgenii Germanovich Skurikhin
  • Patent number: 10040767
    Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: August 7, 2018
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Hanbiao Yang
  • Patent number: 10016354
    Abstract: The present invention relates to compositions containing polymeric, ionic compounds comprising imidazolium groups. In particular, it relates to the use of polymeric, ionic compounds comprising imidazolium groups in personal care compositions and/or in biocide compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: July 10, 2018
    Assignee: BASF SE
    Inventors: Rupert Konradi, Michael Siemer, Bettina Sobotka, Sebastian Koltzenburg, Monika Haberecht, Jean-Pierre Berkan Lindner, Claudia Rosenbaum, Bernd Müller, Richard Riggs, Erica May Wilson Lauterwasser, Jurith Montag
  • Patent number: 9993514
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 12, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre Campos, John David Harling
  • Patent number: 9987254
    Abstract: Ophthalmic composition for the correction of presbyopia. Composition consisting of 2% Pilocarpine, characterized by being diluted to 1% with sterile Balanced Salt Solution (BSS), obtaining 1% pilocarpine (2.5 ml)+bromfenac, 1.8 mgrs of bromfenac (2.5 ml)+sterile Balanced Salt Solution (BSS) (2.5 ml), finally obtaining eye drops of 7.5 ml. It is also possible to obtain a 1.5% and 2% pilocarpine.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: June 5, 2018
    Assignee: EUROCANARIAS OFTALMOLÓGICA, S.L.
    Inventors: Jose Vincent Rodriguez Hernandez, Humberto Carreras Diaz
  • Patent number: 9937163
    Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: April 10, 2018
    Assignee: National University Corporation Chiba University
    Inventors: Kenji Hashimoto, Masaomi Iyo, Kaori Koike
  • Patent number: 9938278
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Christian Gege, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • Patent number: 9867810
    Abstract: The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 16, 2018
    Assignee: Orasis Pharmaceuticals Ltd.
    Inventors: Claes Feinbaum, Franc Salamun, Sudhir Patel
  • Patent number: 9814684
    Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 14, 2017
    Assignee: FLAMEL IRELAND LIMITED
    Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
  • Patent number: 9770439
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
  • Patent number: 9770409
    Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: September 26, 2017
    Assignee: LUXENA PHARMACEUTICALS, INC.
    Inventors: Xiaodong Li, George Lu, Biao Lu
  • Patent number: 9717710
    Abstract: The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: August 1, 2017
    Assignee: vTv THERAPEUTICS LLC
    Inventors: Cesare Orlandi, David J. Clark, Imogene M. Dunn, Maria Carmen Valcarce Lopez, Matthew J. Kostura
  • Patent number: 9539314
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: January 10, 2017
    Assignee: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda M. Guth, Leah Mitchell
  • Patent number: 9527836
    Abstract: An object is to provide a crystal having a new crystal habit of luliconazole and expand the possibility of application to pharmaceuticals. Disclosed is a crystal of luliconazole having such a crystal habit that (020) plane is a specific crystal growth surface.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: December 27, 2016
    Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Takaaki Masuda, Makoto Gotoh, Hideo Kaneda
  • Patent number: 9518152
    Abstract: The object of the present invention is to provide a fundamental therapy to mitochondrial genetic diseases caused by mutation of the mitochondrial (mt)DNA, and a pharmaceutical composition used for the same. The object can be solved by a polyamide compound binding to a target double-stranded mtDNA comprising A/T pair consisting of first A of the following sense-stranded DNA and the corresponding T, A/T pair consisting of 8th A of the following sense-stranded DNA and the corresponding T, G/C pair consisting of 9th G of the following sense-stranded DNA and the corresponding C, G/C pair consisting of 14th G of the following sense-stranded DNA and the corresponding C, T/A pair consisting of 15th T of the following sense-stranded DNA and the corresponding A, or the like, in the double-stranded DNA consisting of the sense-stranded DNA having base sequence of 5?-ATGGCAGAGCCCGGTAATCGCATAA-3? (SEQ ID NO: 1) and the antisense-stranded DNA having base sequence of 5?-TTATGCGATTACCGGGCTCTGCCAT-3? (SEQ ID NO: 2).
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: December 13, 2016
    Inventor: Takamitsu Yano
  • Patent number: 9512108
    Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: December 6, 2016
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Dezhong Wang, Haiping Zhou, Xian Zhang, Hongyan Chen, Di Zhang, Cang Zhang
  • Patent number: 9457020
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 4, 2016
    Assignee: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9308266
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: April 12, 2016
    Assignees: HELSINN HEALTHCARE SA, ROCHE PALO ALTO LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee, Carmine Panuccio
  • Patent number: 9233947
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: January 12, 2016
    Assignee: Janssen Pharmaceutica, NV
    Inventor: Jay M Matthews
  • Patent number: 9226918
    Abstract: This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and/or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compounds that modulate 5-HT3 receptors was found to control withdrawal from morphine in mice and humans.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: January 5, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gary Peltz, David Clark, Lawrence Chu
  • Patent number: 9200309
    Abstract: To provide a method for screening using cultured cells, intended to find a compound which increases the amount of sphingosine-1-phosphate or dihydrosphingosine-1-phosphate by SPL inhibitory activity rapidly, simply and highly sensitively. Provided are: a rapid and simple measurement method employing a scintillation proximity assay (SPA); a method with greatly improved detection sensitivity to the activity of a compound by controlling the concentration of the vitamin B6 group in a culture medium to be used in assaying; and others.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: December 1, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Mamoru Otoyo, Masakazu Tamura
  • Patent number: 9181251
    Abstract: Novel compositions and methods for the treatment and prevention of malaria are disclosed herein.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 10, 2015
    Assignees: University of Central Florida Research Foundation, Inc., Florida Atlantic University Board of Trustees
    Inventors: Debopam Chakrabarti, Amy Wright
  • Patent number: 9173942
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: November 3, 2015
    Assignees: HELSINN HEALTHCARE SA, Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9156818
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with compounds of Formula (I).
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 13, 2015
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Xiaowen Peng, Ce Wang, Lu Ying, Yao-Ling Qiu
  • Patent number: 9145401
    Abstract: An object is to establish an index to prepare a stable pharmaceutical formulation by specifying a related substance of luliconazole which appears depending on the type of a selected solvent in the luliconazole pharmaceutical formulation and which is different from the SE form and the Z form. Disclosed is an amide derivative of luliconazole.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 29, 2015
    Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Takaaki Masuda, Hiroshi Yamaguchi
  • Patent number: 9120830
    Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 1, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Vernon C Alford, Jr., James C Lanter, Raymond A Ng
  • Patent number: 9095576
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: August 4, 2015
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • Patent number: 9090661
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 28, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, John A. McCauley, Steven W. Ludmerer, Kun Liu, Joseph P. Vacca, Hao Wu, Bin Hu, Richard Soll, Fei Sun, Xinghai Wang, Man Yan, Chengren Zhang, Mingwei Zheng, Bin Zhong, Jian Zhu
  • Patent number: 9085554
    Abstract: Disclosed is a method of evaluating stability of a pharmaceutical preparation containing luliconazole. The method includes measuring an amount of production of an SE form of luliconazole represented by following formula (2), an amount of production of a Z form of luliconazole represented by following formula (3) and an amount of production of an amide form of luliconazole represented by following formula (1) after storage under a severe condition or an accelerated condition, and judging that the stability of the pharmaceutical preparation is high if each of the amount of production of the SE form, the amount of production of the Z form and the amount of production of the amide form is not more than 5% by weight with respect to a compounded amount of luliconazole.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 21, 2015
    Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Takaaki Masuda, Hiroshi Yamaguchi
  • Patent number: 9073942
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.
    Type: Grant
    Filed: February 9, 2013
    Date of Patent: July 7, 2015
    Assignee: Lupin Limited
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9073943
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: July 7, 2015
    Assignee: Lupin Limited
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9050271
    Abstract: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: June 9, 2015
    Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Hirokazu Kobayashi, Eiko Kosugi, Nobuo Kubota
  • Patent number: 9050325
    Abstract: A pharmaceutical composition for treating sudden discomfort associated with nausea and vomiting is disclosed which comprises a therapeutically effective amount of Ondansetron or a pharmaceutical salt thereof formulated for intranaal administration in combination with an antimicrobial preservative yielding enhanced stability of the Ondansetron or pharmaceutical salt thereof with a long chain polymer enhancing the viscosity of the composition.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: June 9, 2015
    Inventors: Abdul Zahir, Ryan John Welter
  • Publication number: 20150148384
    Abstract: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 28, 2015
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Christopher F. Bender, Xin Jiang, Xiaofeng Liu, Haizhou Sun, Melean Visnick
  • Patent number: 9040573
    Abstract: An antifungal agent against a fungus of the genus Scytalidium (Scytalidium—dimidiatum, Scytalidium—hyalinum etc.), preferably an antifungal agent for superficial mycosis caused by a fungus of the genus Scytalidium as a pathogenic fungus, which contains luliconazole or a pharmaceutically acceptable salt thereof and/or lanoconazole or a pharmaceutically acceptable salt thereof as active ingredient(s).
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: May 26, 2015
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Hiroyasu Koga, Yasuko Nanjoh, Ryoji Tsuboi
  • Publication number: 20150133517
    Abstract: The invention is directed to sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof and water. The invention is further directed to methods for treating or preventing nausea and emesis associated with cancer treatments by administering sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof to a patient in need thereof.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventors: Kiran Kumar Vangara, Chandeshwari Shivani Chilampalli, Venkat R. Goskonda
  • Publication number: 20150133444
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Venumadhav Janganati, Narsimha Reddy Penthala, Peter A. Crooks, Craig T. Jordan
  • Publication number: 20150133431
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.
    Type: Application
    Filed: July 10, 2014
    Publication date: May 14, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventor: Gary C. Look
  • Publication number: 20150133471
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 14, 2015
    Inventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
  • Patent number: 9029402
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: May 12, 2015
    Assignee: Nivalis Therapeutics, Inc.
    Inventors: Jan Wasley, Gary J. Rosenthal, Xicheng Sun, Sarah Strong, Jian Qiu
  • Patent number: 9029408
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 12, 2015
    Assignees: GTx, Inc., University of Tennessee Research Foundation
    Inventors: Duane D. Miller, Wei Li, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn
  • Publication number: 20150126570
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 7, 2015
    Inventors: Jan Wasley, Gary J. Rosenthal, Xicheng Sun, Sarah Strong, Jian Qiu
  • Patent number: 9023850
    Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Z is O or S; A1, A2, A3 and A4 are independently N or CR1, provided that only one of A1, A2, A3 and A4 is N; and R1, R2, R3 and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling a parasitic nematode comprising contacting the parasitic nematode or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: May 5, 2015
    Assignee: E I du Pont de Nemours and Company
    Inventors: George Philip Lahm, Thomas Francis Pahutski, Jr.
  • Publication number: 20150119406
    Abstract: Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble A? species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular A? aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 30, 2015
    Inventors: Duy H. Hua, Lee-way Jin, Izumi Maezawa, Xinmin Xie
  • Publication number: 20150118285
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 30, 2015
    Inventors: Gilles H. Tapolsky, David W. Osborne
  • Patent number: 9012484
    Abstract: An object is to provide means for improving the solubility of luliconazole. Disclosed is a crystal consisting of luliconazole and short chain alcohol having a number of carbon atom or atoms of 1 to 4.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 21, 2015
    Assignees: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.
    Inventors: Takaaki Masuda, Makoto Gotoh, Yoshiyuki Miyata